Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

Auranofin (AF) is an FDA-approved antirheumatic drug with anticancer properties that acts as a thioredoxin reductase 1 (TrxR) inhibitor. The exact mechanisms through which AF targets cancer cells remain elusive. To shed light on the mode of action, this study provides an in-depth analysis on the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Freire Boullosa, Laurie, Van Loenhout, Jinthe, Flieswasser, Tal, De Waele, Jorrit, Hermans, Christophe, Lambrechts, Hilde, Cuypers, Bart, Laukens, Kris, Bartholomeus, Esther, Siozopoulou, Vasiliki, De Vos, Winnok H., Peeters, Marc, Smits, Evelien L.J., Deben, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles from the Special Issue on Redox Modulation of Cancer Heterogeneity, Therapeutic Resistance and Immunotherapy Efficacy; Edited by Dr. Anita Hjelmeland
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113045/
https://www.ncbi.nlm.nih.gov/pubmed/33812801
http://dx.doi.org/10.1016/j.redox.2021.101949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113045/
https://www.ncbi.nlm.nih.gov/pubmed/33812801
http://dx.doi.org/10.1016/j.redox.2021.101949

Ejemplares similares